U.S. Department of Health & Human Services
National Institutes of Health
NCATS
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
LANADELUMAB
2372V1TKXK
US Approved Rx (2018)
First approved in 2018
General
Names
15
Classification
3
Identifiers
16
Subunits
4
Related Substances
1
LANADELUMAB
2372V1TKXK
US Approved Rx (2018)
First approved in 2018
General
Approval Year
2018
Names
15
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
LANADELUMAB
Official Name
English
Lanadelumab [WHO-DD]
Common Name
English
lanadelumab [INN]
Common Name
English
LANADELUMAB [USAN]
Common Name
English
LANADELUMAB [PURPLE BOOK CDER]
Common Name
English
Showing 1 to 5 of 15 entries
Previous
1
2
3
Next
Classification
3
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Positive
EU ORPHAN DRUG
Positive
Treatment of hereditary angioedema
EU-Orphan Drug
EU/3/15/1551
Drugs used in hereditary angioedema
ATC
BLOOD AND BLOOD FORMING ORGANS
OTHER HEMATOLOGICAL AGENTS
OTHER HEMATOLOGICAL AGENTS
Drugs used in hereditary angioedema
lanadelumab
WHO-ATC
B06AC05
Designated/Approved
ORPHAN DRUG
Designated/Approved
Treatment of hereditary angioedema (HAE)
FDA ORPHAN DRUG
397213
Showing 1 to 3 of 3 entries
Previous
1
Next
Identifiers
16
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
SMS_ID
100000174876
PRIMARY
RXCUI
2055641
PRIMARY
DRUG BANK
DB14597
PRIMARY
CLINICAL_TRIALS.GOV
NCT04070326
PRIMARY
LACTMED
Lanadelumab
PRIMARY
Showing 1 to 5 of 16 entries
Previous
1
2
3
4
Next
Subunits
4
Subunit 0
>SUBUNIT_0
Subunit 1
>SUBUNIT_1
Subunit 2
>SUBUNIT_2
Subunit 3
>SUBUNIT_3
Related Substances
1
ACTIVE MOIETY
2372V1TKXK
LANADELUMAB
